Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder.

bladder cancer prognosis squamous cell carcinoma tumor-infiltrating lymphocytes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Aug 2022
Historique:
received: 03 07 2022
revised: 07 08 2022
accepted: 15 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Background: Tumor infiltrating lymphocytes (TILs) are known as important prognostic biomarkers and build the fundament for immunotherapy. However, the presence of TILs and its impact on outcome in pure squamous cell carcinoma (SCC) of the bladder remains uncertain. Methods: Out of 1600 patients undergoing radical cystectomy, 61 patients revealed pure bladder SCC in the final histopathological specimen. Retrospectively, immunohistochemical staining was performed on a subset of TILs (CD3+, CD4+, CD8+, CD20+). Endpoints were overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS). The Kaplan−Meier method was used to evaluate survival outcomes. Results: Strong infiltration of CD3+ was found in 27 (44%); of CD4+ in 28 (46%); of CD8+ in 26 (43%); and of CD20+ in 27 tumors (44%). Improved OS was observed for strong CD3+ (p < 0.001); CD4+ (p = 0.045); CD8+ (p = 0.001); and CD20+ infiltration (p < 0.001). Increased rates of PFS were observed for CD3+ (p = 0.025) and CD20+ TILs (p = 0.002). In multivariate analyses, strong CD3+ (HR: 0.163, CI: 0.044−0.614) and strong CD8+ TILs (HR: 0.265, CI: 0.081−0.864) were revealed as predictors for OS and the strong infiltration of CD20+ cells (HR: 0.095, CI: 0.019−0.464) for PFS. Conclusions: These first results of TILs in bladder SCC revealed predictive values of CD3+, CD8+ and CD20+.

Identifiants

pubmed: 36010989
pii: cancers14163999
doi: 10.3390/cancers14163999
pmc: PMC9406640
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Transl Oncol. 2019 Mar;12(3):585-595
pubmed: 30682679
Cancer. 2007 Aug 15;110(4):764-9
pubmed: 17614317
Cancer Manag Res. 2019 Apr 12;11:2987-2995
pubmed: 31114346
Virchows Arch. 2015 Oct;467(4):443-8
pubmed: 26215559
Urol Oncol. 2022 Feb;40(2):63.e19-63.e26
pubmed: 34420870
Hematol Oncol Clin North Am. 2015 Apr;29(2):237-52, viii
pubmed: 25836932
Eur Urol. 2015 Aug;68(2):238-53
pubmed: 25709027
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Eur J Cancer. 2020 Jun;132:71-84
pubmed: 32334338
Virchows Arch. 2019 Apr;474(4):463-474
pubmed: 30631935
Cancers (Basel). 2020 Oct 27;12(11):
pubmed: 33121123
Urol Oncol. 2019 Aug;37(8):530.e9-530.e18
pubmed: 31176613
Scand J Immunol. 2020 Feb;91(2):e12830
pubmed: 31823416
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
Urol Oncol. 2019 Jun;37(6):353.e17-353.e24
pubmed: 30704959
Oncoimmunology. 2019 Aug 3;8(11):e1644108
pubmed: 31646091
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
World J Urol. 2021 Jul;39(7):2537-2543
pubmed: 33084922
Eur J Cancer. 1992;29A(1):69-75
pubmed: 1445749
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Oncogenesis. 2018 Jan 23;7(1):2
pubmed: 29358573
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
Cell Mol Immunol. 2019 Jan;16(1):6-18
pubmed: 29628498
Front Oncol. 2018 Aug 23;8:315
pubmed: 30191140
Crit Rev Oncol Hematol. 2019 Mar;135:76-84
pubmed: 30819449
Am J Surg Pathol. 2020 Apr;44(4):536-544
pubmed: 31743129
PLoS One. 2018 Oct 11;13(10):e0205746
pubmed: 30308033
Pathol Res Pract. 2018 Aug;214(8):1074-1080
pubmed: 29803657
Int J Mol Sci. 2020 Nov 09;21(21):
pubmed: 33182484
N Engl J Med. 2021 Jun 3;384(22):2102-2114
pubmed: 34077643
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
J Urol. 2006 Dec;176(6 Pt 1):2414-22; discussion 2422
pubmed: 17085118
Cancer Immun. 2007 Jun 26;7:10
pubmed: 17591743
Cancer Med. 2020 Apr;9(8):2774-2790
pubmed: 32096345
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Investig Clin Urol. 2018 Sep;59(5):285-296
pubmed: 30182073
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
World J Urol. 2016 Feb;34(2):181-7
pubmed: 26055646
Nat Rev Urol. 2018 Feb;15(2):112-124
pubmed: 29205200
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Int J Clin Oncol. 2005 Feb;10(1):20-5
pubmed: 15729596
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183
Cancer Sci. 2019 Feb;110(2):489-498
pubmed: 30548363
Laryngoscope. 2022 Jul;132(7):1334-1339
pubmed: 34415055
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419

Auteurs

Lennert Eismann (L)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Severin Rodler (S)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Alexander Buchner (A)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Gerald Bastian Schulz (GB)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Yannic Volz (Y)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Robert Bischoff (R)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Benedikt Ebner (B)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Thilo Westhofen (T)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Jozefina Casuscelli (J)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Raphaela Waidelich (R)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Christian Stief (C)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Boris Schlenker (B)

Department of Urology, University Hospital Munich, Ludwig-Maximilian-University, 81377 Munich, Germany.

Stephan Ledderose (S)

Department of Pathology, University Hospital Munich, Ludwig-Maximilian-University, 80337 Munich, Germany.

Classifications MeSH